近年来，在国家利好政策的支持下，国内创新药实现蓬勃发展，正逐步成为全球医药创新的重要源头。有数据显示，中国目前拥有1775种first-in-class管线，全球占比19%；license-out(技术授权出海)数量全球占比14%，总金额占比30%。据悉，近年来，国内创新药企与国际大型制药企业的合作日益频繁，合作模式也从单一的技术授权逐步向联合研发、商业化合作等多元化方向发展。如恒瑞医药近日再启...
Source Link近年来，在国家利好政策的支持下，国内创新药实现蓬勃发展，正逐步成为全球医药创新的重要源头。有数据显示，中国目前拥有1775种first-in-class管线，全球占比19%；license-out(技术授权出海)数量全球占比14%，总金额占比30%。据悉，近年来，国内创新药企与国际大型制药企业的合作日益频繁，合作模式也从单一的技术授权逐步向联合研发、商业化合作等多元化方向发展。如恒瑞医药近日再启...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.